Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Schering PEG-Intron Supply Constraints Resolved; Earnings Forecast Cloudy

  • News

Executive Summary

Schering-Plough is ending its supply management program for PEG-Intron (peginterferon alfa-2b) based on enhanced production capacity for the hepatitis C agent

You may also be interested in...



Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication

Three Rivers Pharmaceuticals is amending its ribavirin ANDA to remove references to an 800 mg dose appearing in Schering-Plough's Rebetol labeling

Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication

Three Rivers Pharmaceuticals is amending its ribavirin ANDA to remove references to an 800 mg dose appearing in Schering-Plough's Rebetol labeling

Pharmacia II? Schering’s Hassan Brings In Former Colleagues; Zahn Leaves

Schering-Plough CEO Fred Hassan is bringing in three more former Pharmacia employees under a restructuring plan intended to globalize operations and eliminate several levels of management

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS041408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By